Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized? by Eckel, Robert H. et al.
 
Obesity and Type 2 Diabetes: What Can Be Unified and What
Needs to Be Individualized?
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Eckel, Robert H., Steven E. Kahn, Ele Ferrannini, Allison B.
Goldfine, David M. Nathan, Michael W. Schwartz, Robert J.
Smith, and Steven R. Smith. 2011. Obesity and type 2 diabetes:
What can be unified and what needs to be individualized?
Diabetes Care 34(6): 1424-1430.
Published Version doi:10.2337/dc11-0447
Accessed February 19, 2015 10:45:21 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10403681
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAObesity and Type 2 Diabetes: What Can
Be Uniﬁed and What Needs to Be
Individualized?
ROBERT H. ECKEL, MD
1
STEVEN E. KAHN, MB, CHB
2
ELE FERRANNINI, MD
3
ALLISON B. GOLDFINE, MD
4
DAVID M. NATHAN, MD
5
MICHAEL W. SCHWARTZ, MD
6
ROBERT J. SMITH, MD
7
STEVEN R. SMITH, MD
8
OBJECTIVE—This report examines what is known about the relationship between obesity
and type 2 diabetes and how future research in these areas might be directed to beneﬁtp r e -
vention, interventions, and overall patient care.
RESEARCH DESIGN AND METHODS—An international working group of 32 experts
inthepathophysiology,genetics, clinicaltrials,andclinicalcareofobesityand/or type2diabetes
participated in a conference held on 6–7 January 2011 and cosponsored by The Endocrine
Society, the American Diabetes Association, and the European Association for the Study of Di-
abetes. A writing group comprising eight participants subsequently prepared this summary and
recommendations. Participants reviewed and discussed published literature and their own un-
published data.
RESULTS—Thewritinggroupunanimouslysupportedthesummaryandrecommendationsas
representing the working group’s majority or unanimous opinions.
CONCLUSIONS—The major questions linking obesity to type 2 diabetes that need to be
addressed by combined basic, clinical, and population-based scientiﬁc approaches include the
following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what
mechanisms do obesity and insulin resistance contribute to b-cell decompensation, and if/when
obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3)H o w
doesthedurationoftype2diabetesrelatetothebeneﬁtsofweightreductionbylifestyle,weight-loss
drugs, and/or bariatric surgery onb-cellfunction and glycemia? 4) What is necessary for regulatory
approval of medications and possibly surgical approaches for preventing type 2 diabetes inpatients
with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance
effective and cost-effective interventions for both conditions, including more tailored therapy. To
expeditethisprocess,werecommendfurtherinvestigationintothepathogenesisofthesecoexistent
conditions and innovative approaches to their pharmacological and surgical management.
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M
ost patients with type 2 diabetes
areobese,andtheglobalepidemic
of obesity largely explains the
dramatic increase in the incidence and
prevalenceoftype2diabetesoverthepast
20 years. Currently, over a third (34%) of
U.S.adultsareobese(deﬁnedasBMI.30
kg/m
2), and over 11% of people aged
$20 years have diabetes (1), a prevalence
projected to increase to 21% by 2050 (2).
However, the precise mechanisms link-
ing the two conditions remain unclear,
as does our understanding of interindi-
vidual differences. Improved under-
standing will help advance identiﬁcation
and development of effective treatment
options.
Excess weight is an established risk
factor for type 2 diabetes, yet most obese
individuals do not develop type 2 diabe-
tes. Recent studies have identiﬁed “links”
between obesity and type 2 diabetes in-
volving proinﬂammatory cytokines (tu-
mor necrosis factor and interleukin-6),
insulinresistance,derangedfattyacidme-
tabolism, and cellular processes such as
mitochondrialdysfunctionandendoplas-
mic reticulum stress. These interactions
are complex, with the relative importance
of each unclearly deﬁned. Further genetic
studiesmayelucidateadditionalcommon
pathophysiological pathways for obesity
and diabetes and identify promising new
treatment targets. As physicians fre-
quently prescribe glucose-lowering med-
ications associated with weight gain,
trade-offs between glycemic control and
body weight with current therapeutic op-
tions need more consideration. This issue
is particularly pressing given accumulat-
ing evidence that even modest weight
reduction—whether through lifestyle/
behavioral interventions, obesity medica-
tions, or bariatric surgery—can improve
glycemiccontrolandreducediabetesrisk.
These intriguing, but still largely un-
explored, connections between obesity
and type 2 diabetes suggested the timely
need to convene a group of scientiﬁce x -
pertsintheﬁeldstomorecloselyexamine
underlying pathophysiology and treatment
options for patients with type 2 diabetes
addressing issues of excess weight and
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CONSENSUS REPORTglycemic control simultaneously. Partic-
ipants in the January 2011 conference
(Supplementary Data) were tasked with
examining what is known about the re-
lationship between obesity and type 2
diabetes and the heterogeneity of these
conditions, what needs to be learned, and
how to direct future research in these
areas to advance effective interventions
and improve patient care. What follows
summarizes the major issues addressed
and the outcomes of the discussion.
Mechanisms of obesity-associated
insulin resistance
The inﬂuence of obesity on type 2 di-
abetes risk is determined not only by the
degree of obesity but also by where fat
accumulates. Increased upper body fat
including visceral adiposity, as reﬂected
in increased abdominal girth or waist-to-
hip ratio, is associated with the metabolic
syndrome, type 2 diabetes, and cardio-
vascular disease (3), although underlying
mechanisms remain uncertain. Whether
subcutaneous fat lacks the pathological
effects of visceral fat or is simply a more
neutral storage location, for example, re-
quires further study. Beyond differences
in body fat distribution, emerging evi-
dence suggests that different subtypes of
adipose tissue may be functionally dis-
tinct and affect glucose homeostasis dif-
ferentially. Adult humans have limited
and variable numbers of brown fat cells
(4), which play a role in thermogenesis
andpotentially inﬂuenceenergyexpendi-
ture and obesity susceptibility (5). Im-
proved understanding of the function of
different fat cell types and depots and
their roles in metabolic homeostasis is a
priority for investigation into the patho-
genesis and complications of obesity.
Likewise, adipose tissue is composed of
heterogeneous cell types. Immune cells
within adipose tissue also likely contrib-
ute to systemic metabolic processes. As
the study of adipose biology progresses,
it will be important to consider whether
additionalsubtypesofadipocytesorother
cell types can be identiﬁed to reﬁne
our understanding of obesity complica-
tions and generate novel approaches to
prevention.
At least three distinct mechanisms
have been proposed to link obesity to
insulin resistance and predispose to type
2d i a b e t e s :1) increased production of
adipokines/cytokines, including tumor
necrosis factor-a, resistin, and retinol-
binding protein 4, that contribute to
insulinresistanceaswellasreducedlevels
of adiponectin (6); 2)e c t o p i cf a td e p o s i -
tion, particularly in the liver and perhaps
also in skeletal muscle, and the dysmeta-
bolic sequelae (7); and 3) mitochondrial
dysfunction, evident by decreased mito-
chondrial massand/orfunction(8).Mito-
chondrial dysfunction could be one of
manyimportantunderlyingdefectslinking
obesity to diabetes, both by decreasing in-
sulin sensitivity and by compromising
b-cell function.
Mechanisms of progressive b-cell
dysfunction in obese individuals
The link between obesity and hyperinsu-
linemia,ﬁrstidentiﬁed;50yearsago(9),
reﬂects compensation by insulin-secreting
b-cells to systemic insulin resistance. Al-
though mechanisms underlying this
coupling (e.g., mild hyperglycemia and
raisedlevelsofcirculatingfreefattyacids)
remain elusive, obese normoglycemic in-
dividualshavebothincreasedb-cellmass
and function (9–12).Obesity-induced glu-
cose intolerance reﬂects failure to mount
one or more of these compensatory re-
sponses (13).
Factors predisposing to b-cell de-
compensation could also be primarily ge-
netic or epigenetic. A clear, mechanistic
basis for this decompensation has re-
mained elusive. Genetic studies have
helpedidentifytheroleofsomekeymol-
ecules in b-cell biology that may be im-
portant in this regard. For example,
recentrodentstudieshavedemonstrated
diabetogenic effects of reduced pancre-
atic expressionofthePdx1 gene (14,15).
While these animal studies have demon-
strated that PDX1 deﬁciency relates mech-
anistically to diabetes through b-cell
apoptosis, and PDX1 deﬁciency is linked
t oM O D Y 4( 1 6 ) ,i ti sn o tc l e a ry e tt h a t
PDX1 deﬁciency has a role in common
forms of type 2 diabetes in humans. This
example illustrates how a growing under-
standingofgeneticsandcellularfunctionof
the b-cell can identify potential mediators
predisposing obese individuals to type 2
diabetes and further may provide insights
for the development of new therapeutic
agents.
Genetic factors linking obesity
and diabetes
Genome-wide association scans (GWAS)
and candidate gene approaches now have
identiﬁed;40genesassociatedwithtype
2 diabetes (17,18) and a similar number,
albeit largely different, with obesity. Most
type 2 diabetes genes appear to be related
to b-cell dysfunction, with many fewer
involved in pathwaysrelated toinsulinre-
sistance independent of obesity (19,20).
Not surprisingly, many obesity gene var-
iants appear to be involved in pathways
affecting energy homeostasis. Although
numerousdiabetes- and obesity-associated
genes have been identiﬁed, the known
genes are estimated to predict only 15%
of type 2 diabetes and 5% of obesity risk
(21). Although additional genes with im-
portant roles will undoubtedly be discov-
ered,thislowpredictivepowermayreﬂect
the importance of environmental factors,
less frequent genetic variants with stron-
ger effects, or gene-environment, gene-
gene, and epigenetic interactions that are
not readily identiﬁed through methods
b a s e do np o p u l a t i o ng e n e t i c s .M e t h o d s
for detecting gene-gene interactions exist,
but the population size needed to detect
them is substantially greater than is re-
quired for detection of single genes of rel-
atively small effect. Alternatively, pathway
analyses or a systems biology approach
combining information from DNA varia-
tionswithtranscript,protein,andmetab-
olite proﬁles may better capture the
genetic inﬂuences on metabolism than
studying single genes. One should also
keep in mind that the missing heritability
could be an illusion of inferring additive
genetic effects from epidemiological data
(22).
Does a shared pathogenesis
underlie both obesity and
type 2 diabetes?
Although the link between obesity and
type 2 diabetes is widely held to involve
twodiscretelesions—obesity-inducedin-
sulin resistance and b-cell failure—both
disordersmayshareanunderlying defect.
This “uniﬁed ﬁeld theory” raises ques-
tions about whether defects favoring
progressive weight gain and metabolic
impairment also contribute to b-cell de-
compensation.
One potential link could be sustained
cell exposure to nutrient concentrations
exceeding energy requirements. Deleteri-
ous cellular effects of nutrient excess can
include impaired inﬂammatory signaling,
endoplasmic reticulum stress,excess pro-
duction of reactive oxygen species, mito-
chondrial dysfunction, accumulation of
triglycerides and/or fatty acyl interme-
diates, and activation of serine-threonine
kinases(23).Theseresponsesarenotmu-
tually exclusive, and induction of one
may trigger another, leading to a cascade
of damage. Obesity-associated cellular
injury can in turn recruit and activate
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exacerbate tissue inﬂammation (23,24).
Collectively, these responses contribute
to the pathogenesis of insulin resistance
in the liver, skeletal muscle, and adipose
tissue, and some (e.g., acquired mito-
chondrial dysfunction and inﬂammation)
may occur in b-cells as well via mecha-
nisms discussed above. In susceptible in-
dividuals, therefore, obesity-induced
metabolic impairment can favor insulin
resistance on the one hand and progres-
sive b-cell dysfunction on the other. Re-
duced insulin secretion can in turn
worsen the nutrient excess problem by
raising circulating concentrations of glu-
cose, free fatty acids, and other nutrients.
In this way, a vicious cycle arises whereby
obesity-induced nutrient excess triggers
inﬂammatory responses that cause insu-
lin resistance, placing a greater demand
on the b-cell, and as b-cell function de-
clines the cellular toll taken by nutrient
excess increases. Since not all obese indi-
viduals develop hyperglycemia, however,
an underlying abnormality of the b-cell
must coexist with nutrient excess to pro-
mote type 2 diabetes (13).
Brain neurocircuits governing energy
homeostasis also affect insulin sensitivity
in the liver and perhaps other peripheral
tissues (25), and inﬂammation similar to
that induced by obesity in peripheral
insulin-sensitive tissues also occurs in
these areas of the brain (26). If obesity is
associated with impairment of neurocir-
cuits regulating both energy balance and
insulin action, obesity-induced insulin
resistance may arise not only as a direct
consequence of excessive adipose mass
but via neuronal mechanisms as well.
Whether disturbed neurocircuits also con-
tribute to deteriorating b-cell dysfunction
as obesity and its sequelae progress is an
active area of investigation (27).
Managing body weight by
behavioral change and medications
The dramatic increase in incidence and
prevalence of obesity over the past 50
years, associated in part with major
worldwide changes in caloric intake and
dietary composition, has focused atten-
tion on lifestyle intervention to reverse or
ameliorate caloric imbalance. In general,
programs including individual or group
counseling to modify behavior result in
5–10%weightlossandareeffectivefor6–
12 months, after which weight regain is
the rule. Some longer-term lifestyle inter-
vention studies with sustained interven-
tions demonstrate more durable weight
loss (28,29), with extent of weight loss
in the ﬁrst 3–6 months generally predict-
ing longer-term success. Successful life-
style intervention programs typically
involve self-monitoring of weight, dietary
intake, and activity; behavioral modiﬁca-
tion;frequentcontact;andcaloricbalance
through diet, with or without exercise.
For example, short-term intervention
studies suggest that dietary changes,
which emphasize less fat and reﬁned car-
bohydrates, make it easier to reduce total
caloric intake in obese adults and over-
weight children (30,31).
Medications have been used to assist
in weight loss for almost 80 years, but
adverse effects frequently restrict utility.
Medications have been developed based
on physiological insights, more recently
targeting central nervous system control
of appetite and metabolism, or opportu-
nistically when weight loss was noted as
a side effect of approved medications.
Table 1 lists medications that have been
available and others under development.
In general, weight loss achieved with
these medications ranges from 2 to 8%
greater than placebo, with some sugges-
tion that combination therapy may either
increase weight loss or ameliorate side ef-
fects and increase tolerability. However,
most drug trials last only 6–12 months,
and thus there are few long-term data that
weight loss can be sustained. Moreover,
high drop-out rates, which approach 50%,
are characteristic of many weight-loss trials
andresultinsurvivoreffectsinefﬁcacyanal-
yses, thereby potentially amplifying drug
beneﬁts and limiting generalizability. Fur-
thermore, concern regarding adverse ef-
fects, including cardiovascular disease risk
and central effects (e.g., depression) in
drugscrossingtheblood-brainbarrier,con-
tinue to limit approval and application.
Managing body weight by
bariatric surgery
Health beneﬁts of bariatric surgery, de-
termined largely from nonrandomized
Table 1—Weight-loss medications: past, current, and future
Medication Availability Serious adverse effects
Withdrawn
Fenﬂuramine 1973–1997 Cardiac valvular insufﬁciency and pulmonary hypertension
Dexfenﬂuramine 1996–1997 Cardiac valvular insufﬁciency and pulmonary hypertension
Phenylpropanolamine* 1960–2000 Hemorrhagic stroke
Rimonabant 2006–2009 Depression and suicidal ideation
Sibutramine* 1997–2010 Nonfatal myocardial infarction and nonfatal stroke (in subjects
with preexisting cardiovascular conditions)
Current
Phentermine# 1959–present Palpitations and elevated blood pressure
Orlistat 1999–present Liver injury
Phase 3 trials and current applications to FDA/EMA
Lorcaserin Potential valvular heart disease and psychiatric and cognitive disorders
Bupropion/naltrexone Seizures, palpitations, and transient blood pressure elevations
Topiramate/phentermine Depression, suicidal ideation, cardiovascular events, memory loss,
and birth defects
GLP-1 analogs Pancreatitis
EMA,EuropeanMedicinesAgency;FDA,U.S.FoodandDrugAdministration;GLP-1,glucagon-likepeptide1.*PhenylpropanolamineisstillavailableinsomeEuropean
countries and sibutramine in some South American countries. #Phentermine is one of a class of sympathomimetic drugs that also includes benzphetamine,
diethylpropion, and phendimetrazine.
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Consensus Reportstudies, are being increasingly recog-
nized. These beneﬁts include substantial
andsustained weight loss(32),resolution
of comorbidities such as diabetes, hyper-
tension, and dyslipidemia (33,34), and
reduced myocardial infarction, cancers,
and associated mortality (35). For ex-
treme obesity, surgery is now the pre-
ferred and currently only effective
treatment modality. Acute morbidity
and mortality of surgical approaches
havebeen dramaticallyreduced,enabling
widespread use of these procedures. Fur-
thermore, over the long term, bariatric
surgery might reduce aggregate health
care expenditures (36). There is also a
growing movement toward using surgery
tocontroldiabetes,independentofsevere
excess weight, but there are currently few
scientiﬁcally valid data to support this
clinical path.
Bariatricsurgeryfallsintotwogeneral
categories: purely restrictive procedures
suchasthelaparoscopicadjustablegastric
band devices, which appear to improve
diabetes via weight loss, and procedures
bypassing the proximal gut, such as the
Roux-en-Y gastric bypass (RYGB) or
newer gastric sleeve procedures. The
latter approaches (“metabolic” surgery)
appear to produce unique effects on
enteroendocrine hormones and neuronal
signaling pathways and produce more
weight loss and diabetes remission than
banding alone (34,37). Metabolic surger-
ies are associated with increases in an-
orexigenic and decreases in orexigenic
hormones, changes largely absent in
band or restrictive procedures, and may
explainthedifferentialoutcomes(38).Al-
though mechanisms leading to weight
loss and diabetes remission are only be-
ginning to be understood, the above en-
docrine, peptide, and neural effects may
mediate these beneﬁts because of struc-
tural changes including isolation of the
gastric cardia; exclusion of the distal
stomach, duodenum, and proximal jeju-
num; exposure of the distal intestine to
undigested nutrients; and partial vagot-
omy. Longer duration of diabetes and in-
sulin use, both typically associated with
decreased b-cell function and possibly
surrogatesforreducedb-cellmass,areas-
sociated with reduced postsurgical remis-
sion rates, thus suggesting that residual
b-cell function may be a critical factor
for metabolic beneﬁts (39).
Knowndifferencesinmechanismand
efﬁcacy, along with risks and patient
priorities (e.g., weight loss vs. metabolic/
diabetes goals) already inform the choice
of surgical procedure. However, many
questions remain, including the follow-
ing:Howmuchweightlossisrequiredfor
health beneﬁts? What is the effect of
different interventional methods on
long-term outcomes? What mechanisms
underlie the heterogeneous responses?
Further, regarding diabetes, Is the optimal
timing for treatment the same or different
from obesity? Are b-cells preserved or do
they even grow? Why do not we see the
same efﬁcacy and durability of response
for other obesity-related pathologies (e.g.,
hypertension) asfor glycemic control?On-
goingrandomizedclinicaltrials(40)prom-
ise to answer many questions regarding
patient selection, optimal procedure,
when to intervene, and where initial and
chronic care should be delivered.
Barriers to effective management
A vast array of barriers—ranging from
deﬁcits in basic research to socioeco-
nomicandindividualpsychologicalfactors
beyond the scope of the conference—
undermines current efforts to manage
obesity, particularly in individuals with
type 2 diabetes. Lessons learned from
efforts such as those applied to tobacco
cessation may be quite relevant (41).
Lifestyle programs (especially long-
term) are often plagued by inadequate
reimbursement. Further, there is a lack of
evidence-based individualized goals and
strategies combining lifestyle and medi-
cations, or appreciation of sequential
(stepped) therapy. As mechanisms lead-
ing to obesity and its maintenance are not
fully understood, questions remain about
which interventions, be they lifestyle or
pharmacological, might be most effective
during various stages of weight gain, loss,
and regain.Inaddition,medications under
developmentmaycarryindeterminaterisk.
Likewise, surgery is an imperfect remedy
dueinparttoperceivedrisksandhighcost.
With laparoscopic banding now approved
for BMI .30 kg/m
2 with a comorbidity
such as diabetes or hypertension, 27 mil-
lion Americans would be eligible for sur-
gery. However, the large-scale feasibility of
such an approach is uncertain and com-
pounded by issues related to reimburse-
ment. Thus, the search must continue for
how to implement optimal lifestyle inter-
ventions and to ﬁnd effective drugs and/or
minimally invasive devices.
These barriers are further compli-
cated in the context of type 2 diabetes.
Obese patients with hyperglycemia are
often poorly characterized not only in
termsoftheirhistoryofobesitybutalsoin
the duration of their glucose intolerance.
Further, interventions are typically started
late in the disease, with minimal preven-
tive efforts. In addition, as initial weight
loss is the main determinant of longer-
term weight loss, the typical initial goal
of ;5–10% weight loss may be inade-
quate to produce glycemic control (42).
Furthermore, although controlling body
weight(either by reduction orbypreven-
tion of further rise) improves glycemic
control by ameliorating both insulin resis-
tanceandb-celldysfunction,theimpactof
pharmacologically induced improved gly-
cemic control on body weight varies by
individual drug. Glucose-lowering medi-
cations can be broadly categorized into
t h o s ea s s o c i a t e dw i t hw e i g h tg a i na n d
those essentially weight neutral or pro-
moting weight loss (Table 2). Whether
weight gain offsets any beneﬁt of reduced
glycemia on cardiovascular risk needs to
be determined. Further, weight changes
do not necessarily predict changes in gly-
cemic control (43), and while speciﬁc
therapies may work in certain diabetes
subtypes,theresponsetoglucose-lowering
medicationsvariesconsiderably.Thislatter
topicwas the focus of asimilar workshop
in 2009 on individualizing therapies in
type 2 diabetes (44).
Equally challenging is the problem of
weight regain, which usually follows any
degree of weight loss, however achieved
(Fig.1).Wellstudiedandviewedasanor-
malresponseinleanindividuals,thisphe-
nomenon is equally robust among the
obese. It involves complex, highly inte-
grated physiological responses that are
similar to those invoked in weight-
reduced, nonobese individuals. The bio-
logic basis appears to be the tendency to
defend attained weight, whether normal
or excessive, which seems to be wired in
Table 2—Weight effects of glucose-lowering
medications
Medication class Weight effects
GLP-1 analogs ↓
Pramlintide ↓
Metformin 6 or ↓
a-Glucosidase inhibitors 6
DPP-4 inhibitors 6
Insulin ↑
Sulfonylureas ↑
Glinides ↑
Thiazolidinediones ↑
DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-
like peptide 1.
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against weight loss. Current models of
energy homeostasis predict genetic or
acquired defects in key neurocircuits
that undermine the normal response to
adiposity-related humoral signals. Much
of the basic science in this area has been
performed in animal models of obesity
(genetic or overfeeding); extrapolation
to the pathophysiology of human obesity
remains uncertain.
The panoply of potential mechanisms
defending body weight helps explain why
the ﬁeld is moving toward targeting mul-
tiple pathways by harnessing additive ef-
fects of current drugs, which individually
produce ;5% weight loss (45). A number
of compounds, old and new, alone or in
combination, are being developed. It is
hoped that they may safely achieve the
magnitude of change in body weight, as
wellasotherbeneﬁcialeffectssuchasglu-
cose control, that has been obtained with
some of the surgical approaches.
Recommendations
Elucidate the pathogenesis linking obe-
sity and type 2 diabetes. A better under-
standing of mechanisms linking obesity,
insulinresistance,andtype2diabetes may
ultimately facilitate more individualized
treatment. One future research priority
is to clarify how identiﬁed gene variants
affect glucose, fatty acid, and energy me-
tabolism at both cellular and whole-body
levels. Rather than searching for a single
factor or theory explaining the predispo-
sition to b-cell decompensation in obese
individuals, a multifactorial, synergistic
explanation seems more compatible
with current knowledge. Multiple mech-
anisms may link b-cell dysfunction to
systemic insulin resistance, including
differing cellular responses to nutrient
excess and impaired brain neurocircuits
governing energy homeostasis. One
way to approach this complex patho-
physiologyistoexamineglucose-tolerant
obese patients and study the association
with and progression to b-cell decom-
pensation.
Expand research on heterogeneity. So
far, genetic studies have been limited by a
lack of accurate assessments of pheno-
type. Additional large-scale population-
based analyses addressing more complex
disease determinants of obesity and di-
abetes (beyond single genetic polymor-
phisms) might improve understanding of
the relative impact of genetic and envi-
ronmental factors linking them. Other
priorities include clarifying the genetic
basis for differences in fat distribution
across ethnic groups (46); identifying
factors that control homing of adipose
tissue to the different—visceral versus
subcutaneous—fat depots (47) and adi-
pose tissue angiogenesis (48); and under-
s t a n d i n gt h et i m ec o u r s ea n de x t e n to f
transdifferentiation of brown and white
adipocytes in humans (5).
Human b-cells, including those from
patients with type 2 diabetes, need to be
made more widely available for investiga-
tional use. An additional approach would
be the creation of patient-speciﬁcs t e m
cell–derivedb-cells.Moreover,longitudi-
nal studies of b-cell dysfunction in hu-
mans should address differences in the
amountofweightlossrequiredtodurably
improve b-cell function. Finally, research
to elucidate the intrauterine environ-
ment’s impact on b-cell development
and function may provide further strate-
gic approaches to protecting progressive
b-cell dysfunction.
Develop innovative approaches to phar-
macological and surgical management.
Innovative approaches to managing obe-
sity may lower certain barriers under-
mining treatment of both obesity and
type2diabetes.Forexample,modulating
the incretin axis may beneﬁtb o t he n e r g y
balance and glycemia. Novel pharmaco-
logical development may depend on in-
formation gained from more efﬁcient use
ofgenomic,proteomic,andmetabolomic
approaches and from information learned
from studying weight-loss mechanisms
in bariatric surgery. In addition, co-opting
less traditional organs such as the brain
and gut into the core pathophysiology
of type 2 diabetes may reveal new bio-
markers and/or targets for therapeutic
intervention. Finally, safe and effective cen-
trally acting drugs that decrease appetite
or increase satiety are urgently needed.
However, as regulatory agencies increase
the need for safety testing, fewer new
and innovative approaches for weight
loss are being developed because of the
prolonged time and immense expense
involved.
Emphasize primary prevention of obe-
sity and type 2 diabetes. Currentclinical
approaches to obesity continue to focus
on secondary and tertiary intervention.
Physicians often introduce secondary in-
terventions when patients surpass some
dichotomous BMI threshold or when
patientsself-identify,forcosmeticorhealth
reasons. They introduce tertiary inter-
vention when obesity-related complica-
tions responsive to weight loss, such as
diabetes, hypertension, or sleep apnea,
develop.Becauseweightproblemsdevelop
over the entire life span, however, empha-
sizing obesity prevention is urgent and
must include cooperation of public health
institutions, the school systems, and the
private (e.g., food industry) sector. The
likelihood of sustained beneﬁts of weight
reduction on b-cell function and glycemia
in patients with early-onset versus more
prolonged durations of type 2 diabetes
needs to be determined.
Although intensive lifestyle mod-
iﬁcations and medications have been
Figure 1—Schematic representation of the natural history of obesity. Primary (excess) weight
gain occurs usually over years against the typical background of mild age-related increase in
weightinthegeneralpopulation.Intentionalweightlossfrequentlyisatleastpartiallysuccessful,
but in the vast majority of cases, is followed by weight regain. Weight loss and its maintenance is
the therapeutic goal; prevention of primary weight gain is a societal endeavor.
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velopment of type 2 diabetes in those with
impaired glucose metabolism (28,49), reg-
ulatory authorities have still not approved
medicationsforpreventingtype2diabetes,
nor havethey provideda regulatory frame-
worktodoso.Guidanceonwhatwouldbe
required to approve medications for treat-
inghigh-riskindividualswouldfostermore
scientiﬁc investment in this area and sub-
sequentavailabilityofadditionalpreventive
options.
Adopt a chronic disease model linking
obesity to diabetes care. Current un-
derstanding of both pathophysiology and
management suggests the need to adopt
a chronic disease model of care linking
obesity and diabetes care management sys-
tems. Besides including stepped-care ap-
proaches similar to those used for other
chronic diseases, this model involves bas-
ing interventional (pharmacological and
surgical) approaches on severity, dura-
tion,andindividualrisk/beneﬁt.Thecom-
mon perception that the obesity problem
is insurmountable leads to some degree of
clinicalinertia.Whatisneededissimilarto
what occurred with tobacco—a compre-
hensive social, economic, and workplace
approach to prevention and intervention.
In addition, community-setting approaches
supplemented by physician involvement
can work when combining treatment
modalities (50). Furthermore, multidis-
ciplinary teams including nutritionists,
exercise physiologists, and behavioral/
mental health professionals can achieve
both initial and sustained weight man-
agement and glucose control (28,29).
Thisapproachtoattainingandmaintaining
weight reduction is critically important
both in alleviating the intensive defense
of body weight by multiple biological
systems and in reducing risk of b-cell de-
compensation and, over the long term,
diabetes complications.
Summary and conclusions
Improved understanding of obesity’s
heterogeneity, including interindividual
differences in pathogenesis, propensity
to regain lost weight, development of
obesity-related complications including
diabetes, and response to therapy, is crit-
ical to advance the development of effec-
tive and cost-effective interventions. The
insights that improve obesity prevention
and treatment will almost certainly bene-
ﬁt the incidence and care of type 2 diabe-
tes. The converse may not be true since
current treatments of diabetes can have
differential effects on weight. Even so,
we have reached a point when we can be-
gin to consider innovative and potentially
more effective approaches to managing
both obesity and type 2 diabetes. In-
creased understanding of the pathogene-
sis of obesity and type 2 diabetes, for
example, should not only help differenti-
ate responders from nonresponders but
also make tailored therapy a reality.
Equally beneﬁcial will be incorporating
these ideas into a chronic disease model
of care linking obesity management to di-
abetes care systems, including multidisci-
plinaryapproachestopatientcaredesigned
to preventweight regainthat isalmost uni-
versal when therapy is stopped.
Presently, some of the major ques-
tions linking obesity to type 2 diabetes
that need to be urgently addressed in-
clude the following:
1. Why do not all patients with obesity
develop type 2 diabetes?
2. Through what mechanisms do obesity
and insulin resistance contribute to
b-cell decompensation, and if/when
obesity prevention ensues, how much
reduction in type 2 diabetes incidence
will follow?
3. How does the duration of type 2 di-
abetes relate to the beneﬁts of weight
reductionbylifestyle,weight-lossdrugs,
and/or bariatric surgery on b-cell func-
tion and glycemia?
4. What is necessary for regulatory ap-
proval of medications and possibly
surgical approaches for preventing
type2diabetesinpatientswithobesity?
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